StockNews.com lowered shares of Inogen (NASDAQ:INGN - Free Report) from a buy rating to a hold rating in a research note released on Wednesday morning.
Separately, Needham & Company LLC reiterated a "hold" rating on shares of Inogen in a report on Wednesday.
View Our Latest Stock Analysis on Inogen
Inogen Price Performance
Shares of INGN stock traded up $0.38 during trading hours on Wednesday, hitting $8.33. The company had a trading volume of 408,849 shares, compared to its average volume of 309,250. The company's fifty day moving average is $10.18 and its 200 day moving average is $10.19. Inogen has a fifty-two week low of $6.14 and a fifty-two week high of $13.33. The stock has a market capitalization of $198.40 million, a PE ratio of -3.70 and a beta of 1.02.
Institutional Investors Weigh In On Inogen
Hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its holdings in shares of Inogen by 5.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,710 shares of the medical technology company's stock valued at $245,000 after purchasing an additional 1,318 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Inogen by 2.0% in the 4th quarter. Invesco Ltd. now owns 78,142 shares of the medical technology company's stock valued at $717,000 after purchasing an additional 1,545 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Inogen by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 13,917 shares of the medical technology company's stock valued at $128,000 after purchasing an additional 3,031 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Inogen by 2.7% in the 4th quarter. Bank of America Corp DE now owns 127,326 shares of the medical technology company's stock valued at $1,168,000 after purchasing an additional 3,304 shares in the last quarter. Finally, AlphaQuest LLC acquired a new stake in shares of Inogen in the 4th quarter valued at $43,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
